Pall, NIBRT co-host master class on single-use systems in manufacturing of biopharmaceuticals
Comments (0)Posts tagged: biopharmaceuticals
Comments (0)SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS
Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved ...
Inspiration Biopharmaceuticals Announces Data From OBI-1 Pivotal-Stage Program In Hemophilia At 23rd ISTH Congress
Inspiration Biopharmaceuticals, Inc. (Inspiration) announced data from its clinical development program for OBI-1, an intravenous (IV) recombinant porcine factor VIII product (rpFVIII), intended for the treatment of bleeding in people with hemophilia A with inhibitors and in people with acquired hemophilia. The data were presented in a Scientific Session ...
Keryx Biopharmaceuticals Announces Completion Of Patient Enrollment In KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer. This Phase 3 trial, with over 430 randomized patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food ...
DSM introduces Kremer Method for rapid, cost effective production of biopharmaceuticals
Royal DSM, the global Life Sciences and Materials Sciences company, today announced the introduction of the Kremer Method, an innovative proprietary technology developed by DSM scientists which improves downstream processing of monoclonal antibodies (mAbs) for faster and more cost effective production of biopharmaceuticals
KYTHERA Biopharmaceuticals Presents Patient Reported Outcomes From Phase IIB Study With ATX-101 Demonstrating Reduction Of Submental Fat
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, ...
KYTHERA Biopharmaceuticals Presents Positive Data From Phase IIb Study With ATX-101 Demonstrating Reduction Of Submental Fat
KYTHERA Biopharmaceuticals, Inc. (KYTHERA) presented results from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The Phase IIb study showed ATX-101 was well-tolerated and demonstrated statistically significant efficacy (pPatricia S. Walker, MD, PhD, ...
Data From Phase 2 Study Of Alder Biopharmaceuticals’ Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal Of Anemia In Lung Cancer Patients
Alder Biopharmaceuticals Inc. announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC). After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients ...
ald518, alder, anemia, anti, antibody, biopharmaceuticals, cancer, data, demonstrate, lung, patients, phase, reversal, therapeutic
Keryx Biopharmaceuticals Announces Poster Presentations Of KRX-0401 (Perifosine) At The 52nd Annual Meeting Of The American Society Of Hematology
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced that multiple abstracts for KRX-0401 (perifosine) have been selected for poster presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH), to be held in Orlando, Florida from December 4-7, 2010. Saturday, December 4, 5:30-7:30 p.m. (Hall A3/A4) Abstract Number: ...
Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
BOTHELL, Wash., Nov. 1, 2010 /- Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company's board of directors. Dr. Montgomery, 57, served as founder and chief executive officer of Corus Pharmaceuticals from 2001 through its acquisition in 2006 by Gilead Sciences. ...
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
NEW YORK, Oct. 26 /- Keryx Biopharmaceuticals (Nasdaq: KERX ) reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, ...
Reportlinker Adds Downstream Processing in Biopharmaceuticals – Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
NEW YORK, Oct. 19 /- Reportlinker.com announces that a new market research report is available in its catalogue: Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies http://www.reportlinker.com/p0316266/Downstream-Processing-in-Biopharmaceuticals---Increased-Demand-for-Biologics-Drives-Imp...